| [1] |
Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016 [J]. Journal of the National Cancer Center, 2022, 2(1): 1-9.
|
| [2] |
Cyr DP, Zih FS, Wells BJ, et al. Long-term outcomes following salvage surgery for locally recurrent rectal cancer: A 15-year follow-up study[J]. Eur J Surg Oncol, 2020, 46(6): 1131-1137.
|
| [3] |
CollaborativeBeyond TME. Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes [J]. Br J Surg, 2013, 100(8): 1009-1014.
|
| [4] |
Boyle KM, Sagar PM, Chalmers AG, et al. Surgery for locally recurrent rectal cancer[J]. Dis Colon Rectum, 2005, 48(5): 929-937.
|
| [5] |
Moore HG, Shoup M, Riedel E, et al. Colorectal cancer pelvic recurrences: determinants of resectability[J]. Dis Colon Rectum, 2004, 47(10): 1599-1606.
|
| [6] |
Suzuki K, Gunderson LL, Devine RM, et al. Intraoperative irradiation after palliative surgery for locally recurrent rectal cancer[J]. Cancer, 1995, 75(4): 939-952.
|
| [7] |
Yamada K, Ishizawa T, Niwa K, et al. Patterns of pelvic invasion are prognostic in the treatment of locally recurrent rectal cancer[J]. Br J Surg, 2001, 88(7): 988-993.
|
| [8] |
Belli F, Sorrentino L, Gallino G, et al. A proposal of an updated classification for pelvic relapses of rectal cancer to guide surgical decision-making[J]. J Surg Oncol, 2020, 122(2): 350-359.
|
| [9] |
Sorrentino L, Belli F, Guaglio M, et al. Prediction of R0/R+ surgery by different classifications for locally recurrent rectal cancer [J]. Updates Surg, 2021, 73(2): 539-545.
|
| [10] |
Pilipshen SJ, Heilweil M, Quan SH, et al. Patterns of pelvic recurrence following definitive resections of rectal cancer[J]. Cancer, 1984, 53(6): 1354-1362.
|
| [11] |
Wanebo HJ, Antoniuk P, Koness RJ, et al. Pelvic resection of recurrent rectal cancer: technical considerations and outcomes [J]. Diseases of the Colon and Rectum, 1999, 42(11): 1438-1448.
|
| [12] |
Ngan SY, Burmeister B, Fisher RJ, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: trans-tasman radiation oncology group trial 01.04 [J]. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2012, 30(31): 3827-3833.
|
| [13] |
Chung SY, Takiyama H, Kang JH, et al. Comparison of clinical outcomes between carbon ion radiotherapy and X-ray radiotherapy for reirradiation in locoregional recurrence of rectal cancer [J]. Scientific Reports, 2022, 12(1): 1845.
|
| [14] |
Roeder F, Meldolesi E, Gerum S, et al. Recent advances in (chemo-)radiation therapy for rectal cancer: a comprehensive review[J]. Radiation Oncology (London, England), 2020, 15(1): 262.
|
| [15] |
Lowy AM, Rich TA, Skibber JM, et al. Preoperative infusional chemoradiation, selective intraoperative radiation, and resection for locally advanced pelvic recurrence of colorectal adenocarcinoma [J]. Annals of Surgery, 1996, 223(2): 177-185.
|
| [16] |
Harris CA, Solomon MJ, Heriot AG, et al. The outcomes and patterns of treatment failure after surgery for locally recurrent rectal cancer[J]. Annals of Surgery, 2016, 264(2): 323-329.
|
| [17] |
Ogawa H, Uemura M, Nishimura J, et al. Preoperative chemoradiation followed by extensive pelvic surgery improved the outcome of posterior invasive locally recurrent rectal cancer without deteriorating surgical morbidities: a retrospective, single-institution analysis[J]. Ann Surg Oncol, 2015, 22(13): 4325-4334.
|
| [18] |
Collaborative PelvEx. Factors affecting outcomes following pelvic exenteration for locally recurrent rectal cancer[J]. Br J Surg, 2018, 105(6): 650-657.
|
| [19] |
Valentini V, Morganti AG, Gambacorta MA, et al. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study [J]. Int J Radiat Oncol Biol Phys, 2006, 64(4): 1129-1139.
|
| [20] |
Das P, Delclos ME, Skibber JM, et al. Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation [J]. Int J Radiat Oncol Biol Phys, 2010, 77(1): 60-65.
|
| [21] |
Sorrentino L, Belli F, Valvo F, et al. Neoadjuvant (re)chemoradiation for locally recurrent rectal cancer: Impact of anatomical site of pelvic recurrence on long-term results [J]. Surg Oncol, 2020, 35: 89-96.
|
| [22] |
Nordkamp S, Voogt ELK, Van Zoggel D, et al. Locally recurrent rectal cancer: oncological outcomes with different treatment strategies in two tertiary referral units [J]. Br J Surg, 2022, 109(7): 623-631.
|
| [23] |
Breugom AJ, Van Gijn W, Muller EW, et al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial [J]. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 2015, 26(4): 696-701.
|
| [24] |
Erlandsson J, Lörinc E, Ahlberg M, et al. Tumour regression after radiotherapy for rectal cancer - Results from the randomised Stockholm III trial [J]. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology, 2019, 135: 178-186.
|
| [25] |
Hong TS, Ryan DP. Total neoadjuvant therapy for locally advanced rectal cancer-the new standard of care?[J]. JAMA Oncology, 2018, 4(6): e180070.
|
| [26] |
Bahadoer RR, Dijkstra EA, Van Etten B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial [J]. The Lancet Oncology, 2021, 22(1): 29-42.
|
| [27] |
Conroy T, Bosset JF, Etienne PL, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial [J]. The Lancet Oncology, 2021, 22(5): 702-715.
|
| [28] |
Nielsen M, Rasmussen P, Pedersen B, et al. Early and late outcomes of surgery for locally recurrent rectal cancer: a prospective 10-year study in the total mesorectal excision era[J]. Ann Surg Oncol, 2015, 22(8): 2677-2684.
|
| [29] |
Voogt ELK, Van Zoggel D, Kusters M, et al. Improved outcomes for responders after treatment with induction chemotherapy and chemo(re)irradiation for locally recurrent rectal cancer[J]. Ann Surg Oncol, 2020, 27(9): 3503-3513.
|
| [30] |
Collaborative PelvEx. Surgical and survival outcomes following pelvic exenteration for locally advanced primary rectal cancer: results from an international collaboration[J]. Annals of surgery, 2019, 269(2): 315-321.
|
| [31] |
Hur J, Otegbeye E, Joh HK, et al. Sugar-sweetened beverage intake in adulthood and adolescence and risk of early-onset colorectal cancer among women[J]. Gut, 2021, 70(12): 2330-2336.
|
| [32] |
Douglas JK, Callahan RE, Hothem ZA, et al. Genomic variation as a marker of response to neoadjuvant therapy in locally advanced rectal cancer[J]. Molecular & Cellular Oncology, 2020, 7(3): 1716618.
|
| [33] |
Yang Y, Gu X, Li Z, et al. Whole-exome sequencing of rectal cancer identifies locally recurrent mutations in the Wnt pathway[J]. Aging, 2021, 13(19): 23262-23283.
|
| [34] |
Toomey S, Gunther J, Carr A, et al. Genomic and transcriptomic characterisation of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer[J]. Cancers, 2020, 12(7): 1808.
|
| [35] |
Ott OJ, Gani C, Lindner LH, et al. Neoadjuvant chemoradiation combined with regional hyperthermia in locally advanced or recurrent rectal cancer[J]. Cancers, 2021, 13(6): 1279.
|
| [36] |
Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers[J]. Nature Medicine, 2020, 26(4): 566-576.
|
| [37] |
Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer[J]. The New England Journal of Medicine, 2022, 386(25): 2363-2376.
|